New phenylalkylamine derivatives

Compounds with the general formula I wherein n is 0 or 1, Z is CO or CH(OH), R and R are equal or different and, when equal, hydrogen, methyl, ethyl or propyl and, when different, R is hydrogen and R is methyl, ethyl, propyl or isopropyl, X and Y represent hydrogen, halogen, CF3, CN or an alkyl group, straight or branched having 1-3 carbon atoms, in the ortho, meta or para position provided that when X is in the ortho position and other than hydrogen then Y is other than hydrogen, and when Y is in the ortho position and other than hydrogen then X is other than hydrogen, R represents a straight or branched saturated or unsaturated 1-6 carbon alkyl group, a 3-6 carbon cycloalkyl group, a phenyl group, which may be unsubstituted or may carry a ring substituent X , X preferably being a halogen, or R represents hydrogen, in racemic or optically active form and when Z is CH(OH) also mixtures of diastereomers or a pure diastereomer, with the proviso that the racemate of the compound wherein R and R is hydrogen, X is p-Cl, Y is hydrogen, Z is CO, n is 0 and R is methyl is excluded, or pharmaceutically acceptable salts thereof, processes for the production of said compounds and the use of the said compounds for the treatment of mental disturbances.